President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries.

Charlene Vos

2018-05-07 07:32:00 Mon ET

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries such as Canada, Britain, France, Germany, Japan, and South Korea. As of early-2018, the typical American spends more than $1,100 on prescription drugs per year.

It is true that many Americans take pills on a regular basis, but what sets the U.S. apart from most other OECD countries relates to high drug prices. President Trump now attempts to induce large pharmaceutical companies such as Merck, Johnson & Johnson, Pfizer, Amgen, and GSK etc to increase their medicine prices abroad. This strategic move would create economic incentives for these companies to cut drug prices in America. In light of the high health insurance and medical costs in America, the Trump administration either has to foster competition among biotech firms and pharmaceutical companies, or the Trump administration needs to induce them to voluntarily reduce medicine prices.

President Trump sometimes retorts with the deliberate hyperbole that drugmakers can **get away with murder** in what they charge the government for medication. As the American population enjoys longer human longevity with better medical technology, lower medicine prices seem to have become a necessary evil for big pharma.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

The recent arrest of HuaWei CFO may upend the trade truce between America and China.

Fiona Sydney

2018-12-13 08:30:00 Thursday ET

The recent arrest of HuaWei CFO may upend the trade truce between America and China.

The recent arrest of HuaWei senior executive manager may upend the trade truce between America and China. At the request of several U.S. authorities, Canadi

+See More

AYA Analytica podcast provides fresh insights into the latest stock market issues, economic trends, and investment portfolio strategies.

Daphne Basel

2019-05-30 16:44:00 Thursday ET

AYA Analytica podcast provides fresh insights into the latest stock market issues, economic trends, and investment portfolio strategies.

AYA Analytica finbuzz podcast channel on YouTube May 2019 In this podcast, we discuss several topical issues as of May 2019: (1) Our proprietary alp

+See More

The world now faces an economic inequality crisis with few policy options.

Daisy Harvey

2018-01-04 07:36:00 Thursday ET

The world now faces an economic inequality crisis with few policy options.

The world now faces an economic inequality crisis with few policy options. Some recent U.S. Federal Reserve data suggest that both income and wealth inequal

+See More

BlackRock CEO Larry Fink suggests that corporations should make a positive contribution to society apart from boosting the bottomline.

Olivia London

2018-01-09 08:33:00 Tuesday ET

BlackRock CEO Larry Fink suggests that corporations should make a positive contribution to society apart from boosting the bottomline.

BlackRock CEO Larry Fink emphasizes his key conviction that public corporations should make a positive contribution to society apart from boosting the botto

+See More

E.U. antitrust regulators impose a fine on Qualcomm for advancing its exclusive microchip deal with Apple.

Fiona Sydney

2018-01-17 05:30:00 Wednesday ET

E.U. antitrust regulators impose a fine on Qualcomm for advancing its exclusive microchip deal with Apple.

European Union antitrust regulators impose a fine on Qualcomm for advancing its key exclusive microchip deal with Apple to block out rivals such as Intel an

+See More